{"schema_version":"secwatch.filing_event.v1","accession":"0000918541-23-000136","form_type":"8-K","ticker":"NNBR","cik":"0000918541","company_name":"NN INC","filed_at":"2023-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.397852+00:00","generated_at":"2026-06-08T21:46:51.481717+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"NN Inc. Q3 adj EBITDA up to $14.5M (11.6% of sales); raises 2023 FCF guidance to $10-14M","bullets":["Net sales $124.4M (-2.2% YoY); operating loss $2.7M; net loss $5.1M vs $2.2M prior year.","Adjusted EBITDA $14.5M (11.6% margin) vs $11.8M (9.3%) YoY; free cash flow generation of $11.3M.","Leverage ratio improved to 3.37x from 3.87x sequentially; launched NN Medical division.","Full-year 2023 outlook: revenue $487-497M; adj EBITDA $40-44M; FCF raised to $10-14M.","New COO and CPO added; cost productivity programs expected to yield ~$10M adj EBITDA improvement."],"urls":{"canonical":"https://secwatch.observer/filing/0000918541-23-000136","json":"https://secwatch.observer/filing/0000918541-23-000136.json","markdown":"https://secwatch.observer/filing/0000918541-23-000136.md","text":"https://secwatch.observer/filing/0000918541-23-000136.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/918541/000091854123000136/0000918541-23-000136-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/918541/000091854123000136/nnbr-20231106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T21:46:51.481717+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6bbe0cef1fc6b91faeea6ac9d3ac456eb75d6034","claim":"NN INC reported the third quarter ended September 30, 2023 results: revenue $124.4 million, net income $5.1 million, EPS $0.01 per diluted share. Guidance reaffirmed.","evidence_excerpt":"high-precision components and assemblies, today reported its financial results for the third quarter ended September 30, 2023. Financial and Strategic Highlights • Net sales of $124.4 million, down 2.2% versus prior year period; • Operating loss of $2.7 million and adjusted EBITDA of $14.5 million; • Free cash flow of $11.3 million, up significantly versus prior","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/918541/000091854123000136/0000918541-23-000136-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Revenue","value":"$124.4 million"},{"label":"Net income","value":"$5.1 million"},{"label":"EPS","value":"$0.01 per diluted share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}